Breakthrough in the treatment of HER2-positive metastatic colorectal cancer with tocatinib and trastuzumab 15/12/2022
K medicine won the 7th indication! MSI-H/dMMR bowel cancer is in place in one step, ushering in first-line immunotherapy 20/06/2022 Bowel cancer PD-L1 gene
The latest medication for RAS wild-type colorectal cancer: Avelumab immune combination therapy has a gratifying effect 20/06/2022 Bowel cancer RAS gene
The U.S. Food and Drug Administration approved Encorafenib / Cetuximab for BRAF V600E mutant metastatic colorectal cancer 15/06/2022 Bowel cancer BRAF gene
The U.S. Food and Drug Administration approved Encorafenib / Cetuximab for BRAF V600E mutant metastatic colorectal cancer 09/06/2022 Metastatic colorectal cancer PDGFRA
K medicine won the 7th indication! MSI-H/dMMR bowel cancer is in place in one step, ushering in first-line immunotherapy 09/06/2022 Bowel cancer KRAS, NRAS and BRAF
The latest medication for RAS wild-type colorectal cancer: Avelumab immune combination therapy has a gratifying effect 08/06/2022 Wild-type colorectal cancer wt
What should I do if the targeted chemotherapy for colorectal cancer fails? Double immunotherapy survival rate data extraction group 08/06/2022 Colorectal cancer PD-L1)
KRAS mutant colorectal cancer welcome medicine! Onvansertib significantly improves progress-free survival 08/06/2022 Colorectal cancer HER2，EGFR
